Introduction
============

Kawasaki disease (KD) is a main cause of acquired heart disease in children. At present, the exact etiology of the disease is unknown. The most plausible hypothesis of KD is systemic vasculitis in a genetically susceptible individual, due to an overwhelming immune response triggered by ubiquitous infectious agents. Several studies have attempted to examine the correlation between some respiratory viruses and KD \[[@B1][@B2]\].

In KD patients, respiratory symptoms such as cough (69%), and rhinorrhea (58%) \[[@B3]\] are often observed.

Mycoplasma infection, contributes to the high incidence of pneumonia or bronchitis, mainly in school-aged children. However, younger children are now affected by mycoplasma infection in Korea due to earlier exposures with daycare attendance at a younger age. The symptoms of extrapulmonary mycoplasma infection in children are nonspecific and it can hardly be diagnosed on the basis of clinical symptoms and signs \[[@B4]\]. These symptoms are similar or identical to those of KD; therefore, *Mycoplasma pneumoniae* may be one of the infectious agents that trigger the immune response in KD. In this study, we evaluated the incidence of recent mycoplasma infection and its impact on the clinical course and manifestations of KD.

Materials and Methods
=====================

Medical records of 375 inpatients admitted in a single center (Kyung Hee University Hospital, Seoul, Korea) who were treated for acute stage of KD from January 2000 to December 2013 were retrospectively reviewed.

The Diagnostic Guidelines for KD (American Heart Association \[AHA\], 2004) were used as a reference for the diagnostic criteria of KD \[[@B5]\].

Each patient was treated initially with 2 g/kg intravenous immunoglobulin (IVIG) \[[@B5]\]. Symptoms and signs were observed for 36 to 48 h after termination of IVIG infusion. Additional IVIG, steroid (especially intravenous methylprednisolone), or infliximab was administered when patients were not responsive to the initial IVIG infusion.

After treatment, all KD patients were followed-up with regular two-dimensional (2D) cardiac echocardiography for one year. Abnormalities of coronary arteries were diagnosed by 2D echocardiography, according to the 2004 AHA guidelines \[[@B5]\].

Among 375 patients, 152 (40.5%) patients were also tested for mycoplasma infections by enzyme immunoassay (Serodia-Myco II, Fujirebio, Japan, from 2011). The patients were classified into two groups: 37 (24.3%) with positive results (case group) and 115 (75.7%) with negative results (control group). A positive result was defined as the presence of anti-mycoplasma IgM ≥1:640 or an increase in anti-mycoplasma IgG by more than 4-fold in consecutive tests between 10 to 21 days \[[@B6]\]. As anti-mycoplasma IgM can remain positive for up to 6 to 12 months after infection, the positive group includes acute and recent infections.

Clinical profiles of the two groups were compared. All laboratory data were collected before IVIG was started. Clinical manifestations, respiratory symptoms, and chest X-rays of the patients with persistent fever after treatment were analyzed.

Positive respiratory symptoms were defined as one or more of the following on admission: cough, sputum, or rhinorrhea.

All statistical analyses were performed using SPSS version 22.0 for Windows (IBM, Chicago, Il, USA). *P* values of \<0.05 were considered as statistically significant. Data were presented as mean ± standard deviation. Continuous numeric variables were analyzed by Student *t*-test, and categorical variables were analyzed by Pearson Chi-square test or Fisher\'s exact test.

Results
=======

1. Mycoplasma testing of Kawasaki disease patients {#sec1}
--------------------------------------------------

The numbers of KD patients admitted each year from 2000 to 2013, patients chosen from mycoplasma testing and those positive for mycoplasma infection are shown in [Figure 1](#F1){ref-type="fig"}. From 2000 to 2005, KD patients were rarely tested for anti-mycoplasma antibody or cold agglutinin. In 2006 to 2007 and 2011, there were nationwide mycoplasma epidemics. Thus, in 2012 and 2013, almost all KD patients had anti-mycoplasma antibody testing as part of the initial laboratory tests.

![Distribution of Kawasaki disease patients who underwent testing for mycoplasma and those who tested positive for mycoplasma (January 1, 2000 -- December 31, 2013).\
Myco, *Mycoplasma pneumonia*; KD, Kawasaki disease.](ic-49-38-g001){#F1}

2. Clinical manifestations {#sec2}
--------------------------

Clinical manifestations of the patients are compared in [Table 1](#T1){ref-type="table"}. There were statistically significant differences between the case and control groups in the changes in the extremities, including erythematous changes and/or edema of the hands and feet (78.3% vs. 57.4%, respectively; *P* = 0.031), the duration of fever (6.5 ± 2.5 days vs. 5.4 ± 1.5 days; *P* = 0.047), and in the mean age of KD onset (48.2 ± 32.1 months vs. 31.7 ± 21.7 months; *P* = 0.001).

###### Clinical characteristics of the mycoplasma positive group (case group) and negative group (control group)

![](ic-49-38-i001)

  Variables                              Case group (n = 37)   Control group (n = 115)   *P*-value
  -------------------------------------- --------------------- ------------------------- -----------
  Age (months) (range)                   48.2 ± 32.1           31.7 ± 21.7               0.001^a^
  Fever duration (day) (range)           6.5 ± 2.5             5.4 ± 1.5                 0.047^a^
  Sex (M) \[n (%)\]                      25 (67.6)             67 (58.3)                 0.314
  Clinical criteria \[n (%)\]                                                            
   Bilateral conjunctival injection      35 (94.6)             104 (90.4)                0.431
   Mucosal changes                       34 (91.9)             98 (85.2)                 0.406
   Polymorphous rash                     33 (89.2)             99 (86.0)                 0.783
   Change in the extremities             29 (78.3)             66 (57.4)                 0.031^a^
   Cervical lymphadenopathy              26 (70.2)             71 (61.7)                 0.348
  Incomplete KD presentation \[n (%)\]   5 (13.5)              22 (19.1)                 0.437
  Respiratory symptoms \[n (%)\]         13 (35.1)             48 (41.7)                 0.476
  Initial IVIG resistance \[n (%)\]      5 (13.5)              16 (14.0)                 0.951
  Coronary artery lesions \[n (%)\]      5 (14.0)              16 (14.0)                 0.937

KD, Kawasaki disease; IVIG, intravenous immunoglobulin

Values shown marked with ^a^ *P* \<0.05

The case and control groups did not differ significantly in gender (*P* = 0.314), and in other clinical criteria of KD, such as presence or absence of bilateral conjunctival injection (94.6% vs. 90.4%; *P* = 0.431), mucosal changes (91.9% vs. 85.2%; *P* = 0.406), polymorphous rash (89.2% vs. 86.0%; *P* = 0.783), and cervical lymphadenopathy (70.2% vs. 61.7%, *P* = 0.348). No differences between the two groups were found in the presence of incomplete KD (*P* =0.437), respiratory symptoms (*P* = 0.476), response to IVIG (*P* = 0.951), and development of coronary artery lesions (*P* = 0.937).

3. Laboratory data {#sec3}
------------------

No significant differences between the case and control groups were found in laboratory values (hemoglobin \[Hb\], white blood cell \[WBC\] count, C-reactive protein \[CRP\], aspartate transaminase \[AST\], alanine transaminase \[ALT\], and pyuria; [Table 2](#T2){ref-type="table"}), and pro-brain natriuretic peptide (proBNP) concentration ([Table 3](#T3){ref-type="table"}).

###### Laboratory values in the case and control groups

![](ic-49-38-i002)

  Laboratory values                 Case group (n = 37)   Control group (n = 115)   *P*-value
  --------------------------------- --------------------- ------------------------- -----------
  Hb, g/dL                          11.5 ± 0.9            11.4 ± 1.0                0.614
  WBC count, × 10^3^/mL             12.8 ± 7.0            13.5 ± 6.2                0.742
  CRP, mg/dL                        9.9 ± 6.9             9.5 ± 6.6                 0.943
  AST, U/L                          102 ± 128.5           68.7 ± 115.1              0.16
  ALT, U/L                          98 ± 136.5            80 ± 139.4                0.49
  Pyuria(\>10 WBCs/HPF) \[n (%)\]   35.1                  41.7                      0.476

WBC, white blood cells; CRP, C-reactive protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HPF, high power field.

Mean values, percentages, and standard deviations are shown.

###### Concentration of pro-brain natriuretic peptide (proBNP) on admission in patients from the case and control groups

![](ic-49-38-i003)

  Laboratory values   Case group (n = 27)   Control group (n = 70)   *P*-value
  ------------------- --------------------- ------------------------ -----------
  ProBNP, pg/mL       1187.2 ± 1,397.0      1,168.0 ± 2,511.7        0.459

4. Patients with persistent fever after resolution of acute-stage KD {#sec4}
--------------------------------------------------------------------

In 7 (18.9%) patients from the case group, despite an improvement in symptoms of acute-stage KD and desquamation of the extremities after the first or second IVIG treatment, fever persisted for an additional 48 to 165 hours after the completion of IVIG infusion. Their clinical characteristics are listed in [Table 4](#T4){ref-type="table"}. Among these 7 patients, 2 had respiratory symptoms on the first day of admission, 4 patients had chest X-rays consistent with pneumonia and 2 had coronary artery lesions on echocardiography. Five patients had a secondary IVIG infusion of 2 g/kg; and neither corticosteroid nor infliximab were used for secondary treatment of acute-stage KD.

###### Clinical profiles of children with persistent fever after IVIG who were proved to be mycoplasma-positive (n = 7).

![](ic-49-38-i004)

  No.   Sex/age   Fever duration after first IVIG (h)   2nd IVIG   Respiratory symptoms on admission   Chest X-ray reading   CAL   Antibiotics   Time to start antibiotics after first IVIG finished (h)   Fever subsided after antibiotics started (h)
  ----- --------- ------------------------------------- ---------- ----------------------------------- --------------------- ----- ------------- --------------------------------------------------------- ----------------------------------------------
  1     M/23m     57                                    N          Y                                   BLL pneumonia         N     AZM           50                                                        48
  2     F/5Y      158                                   Y          N                                   RLL pneumonia         N     AZM           72                                                        140
  3     F/7Y      48                                    Y          N                                   Unremarkable          N     CLR           24                                                        24
  4     M/5Y      165                                   Y          N                                   Unremarkable          N     AZM           162                                                       96
  5     M/4Y      120                                   N          Y                                   RLF pneumonia         Y     AZM           168                                                       12
  6     F/5Y      48                                    Y          N                                   RLF pneumonia         N     CLR           30                                                        144
  7     M/14m     48                                    Y          N                                   unremarkable          Y     CLR           72                                                        24

IVIG, intravenous immunoglobulin; CAL, coronary artery lesions; BLL, both lung field; AZM, azithromycin; RLL, right lower lung field; RLF, right lung field; CLR, clarithromycin.

Discussion
==========

Of the 375 KD patients assessed during the study, 152 patients were tested for mycoplasma, and 37 patients had positive results. Before 2007, the patients were tested for mycoplasma infection in the presence of cough, rhinorrhea or persistent fever. From 2007, when there was a mycoplasma epidemic most patients admitted for KD were initially tested for mycoplasma infections. The group with positive tests had longer fever duration, older age, and more changes in the extremities. Seven (18.9%) patients in the case group had persistent fever even after resolution of the acute stage of KD.

The mean age of KD patients is generally considered to be 3 years; all patients are younger than 5 years \[[@B7]\]. However, in one study, the age distribution was 9 to 11 months \[[@B3]\]. Because mycoplasma infection was common in preschool-aged children in our study, the onset age of KD may be slightly higher than in other studies. On the other hand, the youngest mycoplasma-positive child with KD in our study was 2 months of age. Mycoplasma infection in Korea is not limited to school-aged children because many infants and younger children are cared for in daycare centers. Therefore, differential diagnosis between KD and mycoplasma infection is becoming more important in Korea. According to our study, recent mycoplasma infection and KD co-occur more often in older children. Immune modulation of *M. pneumoniae* infection may results in cross-reaction between bacterial and human cell components, and autoimmunity may contribute to the pathogenesis of KD \[[@B8]\].

In our study, the mean fever duration was 6.5 days in the mycoplasma-positive group and 5.4 days, in the negative group. In general, fever duration in patients with KD is more than 5 days; it can persist to 14 days when mycoplasma infection present \[[@B9]\]. Mycoplasma infection alone has a longer fever duration than KD has. In a study by Lee et al. \[[@B8]\], the mean fever duration was 9.2 days in the mycoplasma-positive group and 6.9 days in the negative group, which was longer than both groups in our study.

In our study, changes in the extremities differed significantly between the mycoplasma-positive and negative groups. The detailed mechanism of the changes of the extremities in the acute stage of KD and the following subacute stage is not well understood. Hand and foot changes in patients with mycoplasma infection have been described in a case report by Greco et al., 2007 \[[@B10]\]. Although the pathogenesis of the changes has not been fully elucidated, they may be explained by hypersensitivity vasculitis. The patient reported by Greco et al. had extrapulmonary symptoms of *M. pneumoniae* infection, namely cutaneous vasculitis, as well as inflammation and necrosis of small blood vessel walls.

Of the 37 case group patients, 7 patients had persistent fever after the resolution of acute symptoms and laboratory abnormalities. They were reevaluated to identify the cause of sustained fever after use of IVIG. Laboratory studies including WBC, Hb, Hct, CRP, AST, ALT and immunology assay were within normal level. Respiratory viral polymerase chain reaction (PCR) was not available for the group. Clarithromycin (CLR), or azithromycin (AZM) was given to the patients with subsequent subsiding of fever.

One of these 7 cases (case 4) is described in [Figure 2](#F2){ref-type="fig"}. A 5-year-old male presented with all symptoms of acute-stage KD and we started treatment with IVIG on the first hospital day. Almost 48 hours after the end of the first IVIG treatment, fever and erythema of the hands and feet remained. The patient was regarded as having refractory acute stage of KD and the second IVIG treatment was infused on day 4. On day 8, desquamation of hands and feet was observed yet fever persisted. During evaluation for the sustained fever, CRP was decreased and other laboratory findings were normalized, however anti-mycoplasma IgM titer remained high (\>1:1,280) until day 10. Azithromycin was administered and fever subsided on day 14. Initially, the child had no respiratory symptoms and showed unremarkable chest X-ray findings. A follow-up chest X-ray was also unremarkable. Therefore, mycoplasma infection may be a cause of persistent fever after the resolution of acute-stage KD.

![Clinical course of case No. 4 (see [Table 3](#T3){ref-type="table"})\
IVIG, intravenous immunoglobulin; HD, hospital day; BT, body temperature; CRP, c-reactive protein](ic-49-38-g002){#F2}

In our study, 11 (29.7%) of the 37 case group patients were treated with macrolide antibiotics. Antibiotics were not used in the other patients.

Mycoplasma is known as a main cause of pneumonia in school-aged children. Our results seem to indicate high incidence of recent mycoplasma infection in preschool-aged children. Mycoplasma infection has many extrapulmonary symptoms such as arthritis, hemolytic anemia and other systemic symptoms \[[@B11]\]. Symptoms of mycoplasma infection may be similar to those of KD and concomitant infection with mycoplasma in KD patients is also possible. Therefore, it is important to distinguish recent mycoplasma infection from KD in patients with fever that persists despite appropriate management of KD.

A study revealed some factors which predict refractory KD: male gender, cervical lymphadenopathy, decreased platelet count, changes of extremities, increased total bilirubin, increased alkaline phosphatase (ALP), elevated lactate dehydrogenase(LDH), and elevated CRP \[[@B12]\]. In another study by Kim et al. \[[@B13]\], CRP, AST, ALT, and the neutrophil differential were higher while the lymphocyte differential, protein, albumin, platelet count, and total cholesterol were decreased in the refractory group.

IVIG with conventional antibiotics in early treatment of macrolide-resistant mycoplasma pneumonia can prevent disease progression. In 4 patients with macrolide-resistant mycoplasma pneumonia in the study by Youn et al. \[[@B14]\], corticosteroid was previously used for immune modulation. In those patients with remaining pneumonia, IVIG treatment improved the lesions within 2 days.

There are a few limitations in our study. Some laboratory findings, for example, urine WBC, had either positive or negative categorical values. Early diagnosis of mycoplasma infection was challenging, especially in its acute stage, because of a low antibody level. In addition, respiratory virus RT-PCR testing was not performed for all patients in this study.

In this study, most patients admitted for treatment of KD from 2007 were initially tested for possible mycoplasma infection. Cross-reactivities of IVIG and anti-mycoplasma antibody may be considered in patients who were admitted before 2007. The false-positive IgM ratio of enzyme immunoassay methods vary from 2.8 - 14.9% \[[@B15]\]. When PCR is combined with the immunoassay method, the sensitivity of rapid diagnosis is 95% \[[@B16]\].

In conclusion, recent mycoplasma infection was somewhat related to KD. The mean age of the mycoplasma-positive group was 48.2 months, which was significantly older than the negative group.

When fever persists after the resolution of acute symptoms and laboratory abnormalities of KD, further evaluation and treatment for mycoplasma infection may be considered, especially in preschool-aged children.
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